{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:51:50Z","timestamp":1791669110220,"version":"4.3.4"},"reference-count":66,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2020,5,1]]},"DOI":"10.1001\/jamainternmed.2020.0249","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T11:30:58Z","timestamp":1583753458000},"page":"728","source":"Crossref","is-referenced-by-count":175,"title":["Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms"],"prefix":"10.1001","volume":"180","author":[{"given":"Raymond F.","family":"Anton","sequence":"first","affiliation":[{"name":"Addiction Sciences Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Latham","sequence":"additional","affiliation":[{"name":"Addiction Sciences Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Voronin","sequence":"additional","affiliation":[{"name":"Addiction Sciences Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Book","sequence":"additional","affiliation":[{"name":"Addiction Sciences Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Addiction Sciences Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Prisciandaro","sequence":"additional","affiliation":[{"name":"Addiction Sciences Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Bristol","sequence":"additional","affiliation":[{"name":"Addiction Sciences Division, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9","key":"ioi200010r1","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1001\/jamapsychiatry.2017.2161","article-title":"Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United States, 2001-2002 to 2012-2013: results from the National Epidemiologic Survey on Alcohol and Related Conditions.","volume":"74","author":"Grant","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"ioi200010r2","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1111\/acer.12331","article-title":"Burden of disease associated with alcohol use disorders in the United States.","volume":"38","author":"Rehm","year":"2014","journal-title":"Alcohol Clin Exp Res"},{"issue":"2","key":"ioi200010r3","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1080\/08897077.2015.1133472","article-title":"Potential medications for the treatment of alcohol use disorder: an evaluation of clinical efficacy and safety.","volume":"37","author":"Litten","year":"2016","journal-title":"Subst Abus"},{"issue":"6","key":"ioi200010r4","first-page":"733","article-title":"Clinical relevance of the distinction between alcohol dependence with and without a physiological component.","volume":"155","author":"Schuckit","year":"1998","journal-title":"Am J Psychiatry"},{"issue":"1","key":"ioi200010r5","first-page":"73","article-title":"Prevalence, trends, and incidence of alcohol withdrawal symptoms: analysis of general population and clinical samples.","volume":"22","author":"Caetano","year":"1998","journal-title":"Alcohol Health Res World"},{"issue":"5","key":"ioi200010r6","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/01.ALC.0000067980.18461.33","article-title":"A 5-year prospective evaluation of DSM-IV alcohol dependence with and without a physiological component.","volume":"27","author":"Schuckit","year":"2003","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"ioi200010r7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/ADM.0b013e318044ce4f","article-title":"Impact of lifetime alcohol quit attempts and medicated detoxifications on time to relapse during an index alcohol detoxification.","volume":"1","author":"Wright","year":"2007","journal-title":"J Addict Med"},{"issue":"3","key":"ioi200010r8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1055\/s-2007-979203","article-title":"Treatment of alcohol withdrawal syndrome with gabapentin.","volume":"32","author":"Bonnet","year":"1999","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"ioi200010r9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1369-1600.2008.00133.x","article-title":"Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin.","volume":"14","author":"Mason","year":"2009","journal-title":"Addict Biol"},{"issue":"1","key":"ioi200010r10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s002130100919","article-title":"Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis.","volume":"160","author":"O\u2019Malley","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"issue":"9","key":"ioi200010r11","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1097\/01.ALC.0000139704.88862.01","article-title":"Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers.","volume":"28","author":"Drobes","year":"2004","journal-title":"Alcohol Clin Exp Res"},{"issue":"7","key":"ioi200010r12","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1056\/NEJMct0801733","article-title":"Naltrexone for the management of alcohol dependence.","volume":"359","author":"Anton","year":"2008","journal-title":"N Engl J Med"},{"issue":"9","key":"ioi200010r13","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1001\/archpsyc.64.9.1069","article-title":"Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study.","volume":"64","author":"Ray","year":"2007","journal-title":"Arch Gen Psychiatry"},{"issue":"13","key":"ioi200010r14","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1038\/npp.2017.74","article-title":"Predictors of naltrexone response in a randomized trial: reward-related brain activation, OPRM1 genotype, and smoking status.","volume":"42","author":"Schacht","year":"2017","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"ioi200010r15","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.bcp.2007.06.039","article-title":"Glutamatergic substrates of drug addiction and alcoholism.","volume":"75","author":"Gass","year":"2008","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"ioi200010r16","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nrd2828","article-title":"Development of pharmacotherapies for drug addiction: a Rosetta stone approach.","volume":"8","author":"Koob","year":"2009","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"ioi200010r17","first-page":"13","article-title":"Neurochemical mechanisms underlying alcohol withdrawal.","volume":"22","author":"Littleton","year":"1998","journal-title":"Alcohol Health Res World"},{"issue":"24","key":"ioi200010r18","doi-asserted-by":"publisher","first-page":"10663","DOI":"10.1523\/JNEUROSCI.18-24-10663.1998","article-title":"Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens.","volume":"18","author":"Gonzales","year":"1998","journal-title":"J Neurosci"},{"issue":"5","key":"ioi200010r19","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1111\/adb.v24.5","article-title":"The dopamine transporter VNTR polymorphism moderates the relationship between acute response to alcohol and future alcohol use disorder symptoms.","volume":"24","author":"Schacht","year":"2019","journal-title":"Addict Biol"},{"issue":"1","key":"ioi200010r20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/npp.2011.216","article-title":"Novel therapeutic strategies for alcohol and drug addiction: focus on GABA, ion channels and transcranial magnetic stimulation.","volume":"37","author":"Addolorato","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"ioi200010r21","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1001\/archpsyc.63.9.957","article-title":"Gamma-aminobutyric acid type A receptors and alcoholism: intoxication, dependence, vulnerability, and treatment.","volume":"63","author":"Krystal","year":"2006","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"ioi200010r22","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.semcdb.2006.09.003","article-title":"Alpha2delta and the mechanism of action of gabapentin in the treatment of pain.","volume":"17","author":"Maneuf","year":"2006","journal-title":"Semin Cell Dev Biol"},{"issue":"4","key":"ioi200010r23","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1124\/pr.114.009654","article-title":"The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential.","volume":"67","author":"Zamponi","year":"2015","journal-title":"Pharmacol Rev"},{"issue":"9","key":"ioi200010r24","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1073\/pnas.0708930105","article-title":"Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin.","volume":"105","author":"Hendrich","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"ioi200010r25","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.coph.2005.11.003","article-title":"The mechanisms of action of gabapentin and pregabalin.","volume":"6","author":"Sills","year":"2006","journal-title":"Curr Opin Pharmacol"},{"issue":"6","key":"ioi200010r26","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1097\/ALN.0b013e318254e6fd","article-title":"Gabapentin inhibits ?-amino butyric acid release in the locus coeruleus but not in the spinal dorsal horn after peripheral nerve injury in rats.","volume":"116","author":"Yoshizumi","year":"2012","journal-title":"Anesthesiology"},{"key":"ioi200010r27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.neuropharm.2014.01.040","article-title":"Gabapentin increases extracellular glutamatergic level in the locus coeruleus via astroglial glutamate transporter-dependent mechanisms.","volume":"81","author":"Suto","year":"2014","journal-title":"Neuropharmacology"},{"issue":"13","key":"ioi200010r28","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1038\/npp.2012.142","article-title":"The impact of gabapentin administration on brain GABA and glutamate concentrations: a 7T 1H-MRS study.","volume":"37","author":"Cai","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"ioi200010r29","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/10550490500419110","article-title":"A randomized, open-label, controlled trial of gabapentin and phenobarbital in the treatment of alcohol withdrawal.","volume":"15","author":"Mariani","year":"2006","journal-title":"Am J Addict"},{"issue":"9","key":"ioi200010r30","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1111\/acer.2009.33.issue-9","article-title":"A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal.","volume":"33","author":"Myrick","year":"2009","journal-title":"Alcohol Clin Exp Res"},{"issue":"11","key":"ioi200010r31","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.4088\/JCP.v68n1108","article-title":"Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial.","volume":"68","author":"Furieri","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"ioi200010r32","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1176\/ajp.157.1.151","article-title":"Gabapentin treatment for insomnia associated with alcohol dependence.","volume":"157","author":"Karam-Hage","year":"2000","journal-title":"Am J Psychiatry"},{"issue":"5","key":"ioi200010r33","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1046\/j.1440-1819.2003.01161.x","article-title":"Open pilot study of gabapentin versus trazodone to treat insomnia in alcoholic outpatients.","volume":"57","author":"Karam-Hage","year":"2003","journal-title":"Psychiatry Clin Neurosci"},{"issue":"4","key":"ioi200010r34","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/JCP.0b013e3181aba6a4","article-title":"Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms.","volume":"29","author":"Anton","year":"2009","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"ioi200010r35","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1176\/appi.ajp.2011.10101436","article-title":"Gabapentin combined with naltrexone for the treatment of alcohol dependence.","volume":"168","author":"Anton","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"22","key":"ioi200010r36","doi-asserted-by":"publisher","first-page":"5762","DOI":"10.1523\/JNEUROSCI.0575-08.2008","article-title":"Cellular and behavioral interactions of gabapentin with alcohol dependence.","volume":"28","author":"Roberto","year":"2008","journal-title":"J Neurosci"},{"issue":"1","key":"ioi200010r37","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1001\/jamainternmed.2013.11950","article-title":"Gabapentin treatment for alcohol dependence: a randomized clinical trial.","volume":"174","author":"Mason","year":"2014","journal-title":"JAMA Intern Med"},{"issue":"1","key":"ioi200010r38","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/acer.13917","article-title":"Gabapentin enacarbil extended-release for alcohol use disorder: a randomized, double-blind, placebo-controlled, multisite trial assessing efficacy and safety.","volume":"43","author":"Falk","year":"2019","journal-title":"Alcohol Clin Exp Res"},{"key":"ioi200010r39","first-page":"27","article-title":"Cognitive side effects of anticonvulsants.","volume":"62","author":"Goldberg","year":"2001","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"ioi200010r40","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1111\/acer.2011.35.issue-11","article-title":"Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence.","volume":"35","author":"Schacht","year":"2011","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"ioi200010r41","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.drugalcdep.2005.10.008","article-title":"The acute effects of gabapentin in combination with alcohol in heavy drinkers.","volume":"83","author":"Bisaga","year":"2006","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"ioi200010r42","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/acer.2007.31.issue-2","article-title":"A double-blind evaluation of gabapentin on alcohol effects and drinking in a clinical laboratory paradigm.","volume":"31","author":"Myrick","year":"2007","journal-title":"Alcohol Clin Exp Res"},{"issue":"228","key":"ioi200010r44","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3389\/fpsyt.2019.00228","article-title":"Use of gabapentin in the treatment of substance use and psychiatric disorders: a systematic review.","volume":"10","author":"Ahmed","year":"2019","journal-title":"Front Psychiatry"},{"issue":"11","key":"ioi200010r45","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/add.1989.84.issue-11","article-title":"Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar).","volume":"84","author":"Sullivan","year":"1989","journal-title":"Br J Addict"},{"issue":"17","key":"ioi200010r47","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","article-title":"Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.","volume":"295","author":"Anton","year":"2006","journal-title":"JAMA"},{"issue":"15","key":"ioi200010r48","doi-asserted-by":"crossref","first-page":"157","DOI":"10.15288\/jsas.2005.s15.157","article-title":"The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field.","author":"Johnson","year":"2005","journal-title":"J Stud Alcohol Suppl"},{"issue":"4","key":"ioi200010r49","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1530-0277.2007.00345.x","article-title":"Multidimensionality of the Alcohol Withdrawal Symptom Checklist: a factor analysis of the Alcohol Withdrawal Symptom Checklist and CIWA-Ar.","volume":"31","author":"Pittman","year":"2007","journal-title":"Alcohol Clin Exp Res"},{"issue":"3","key":"ioi200010r50","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1037\/0021-843X.91.3.199","article-title":"Alcohol dependence syndrome: measurement and validation.","volume":"91","author":"Skinner","year":"1982","journal-title":"J Abnorm Psychol"},{"issue":"3","key":"ioi200010r51","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1001\/archpsyc.1996.01830030047008","article-title":"The obsessive compulsive drinking scale: a new method of assessing outcome in alcoholism treatment studies.","volume":"53","author":"Anton","year":"1996","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"ioi200010r52","doi-asserted-by":"publisher","first-page":"358","DOI":"10.15288\/jsa.1997.58.358","article-title":"The reliability of Form 90: an instrument for assessing alcohol treatment outcome.","volume":"58","author":"Tonigan","year":"1997","journal-title":"J Stud Alcohol"},{"issue":"6","key":"ioi200010r53","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1111\/acer.2010.34.issue-6","article-title":"Alcohol biomarkers in applied settings: recent advances and future research opportunities.","volume":"34","author":"Litten","year":"2010","journal-title":"Alcohol Clin Exp Res"},{"issue":"11","key":"ioi200010r54","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1515\/CCLM.2010.322","article-title":"Toward standardization of carbohydrate-deficient transferrin (CDT) measurements: II. performance of a laboratory network running the HPLC candidate reference measurement procedure and evaluation of a candidate reference material.","volume":"48","author":"Helander","year":"2010","journal-title":"Clin Chem Lab Med"},{"issue":"12","key":"ioi200010r56","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1111\/acer.2010.34.issue-12","article-title":"Percentage of subjects with no heavy drinking days: evaluation as an efficacy endpoint for alcohol clinical trials.","volume":"34","author":"Falk","year":"2010","journal-title":"Alcohol Clin Exp Res"},{"issue":"4","key":"ioi200010r58","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1111\/acer.2018.42.issue-4","article-title":"Nicotine-use\/smoking is associated with the efficacy of naltrexone in the treatment of alcohol dependence.","volume":"42","author":"Anton","year":"2018","journal-title":"Alcohol Clin Exp Res"},{"issue":"26","key":"ioi200010r59","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJM198806303182605","article-title":"An assessment of clinically useful measures of the consequences of treatment.","volume":"318","author":"Laupacis","year":"1988","journal-title":"N Engl J Med"},{"issue":"8","key":"ioi200010r60","first-page":"1215","article-title":"Carbohydrate-deficient transferrin and gamma-glutamyltransferase for the detection and monitoring of alcohol use: results from a multisite study.","volume":"26","author":"Anton","year":"2002","journal-title":"Alcohol Clin Exp Res"},{"issue":"11","key":"ioi200010r61","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1373\/clinchem.2003.023341","article-title":"Improved HPLC method for carbohydrate-deficient transferrin in serum.","volume":"49","author":"Helander","year":"2003","journal-title":"Clin Chem"},{"issue":"9","key":"ioi200010r62","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1111\/add.v114.9","article-title":"A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder.","volume":"114","author":"Kranzler","year":"2019","journal-title":"Addiction"},{"issue":"5","key":"ioi200010r63","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.pnpbp.2007.09.021","article-title":"New developments for the pharmacological treatment of alcohol withdrawal syndrome. a focus on non-benzodiazepine GABAergic medications.","volume":"32","author":"Leggio","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"ioi200010r64","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/npp.2013.256","article-title":"Increased extracellular glutamate in the nucleus accumbens promotes excessive ethanol drinking in ethanol dependent mice.","volume":"39","author":"Griffin","year":"2014","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"ioi200010r65","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/adb.2012.17.issue-2","article-title":"Brain region-specific gene expression changes after chronic intermittent ethanol exposure and early withdrawal in C57BL\/6J mice.","volume":"17","author":"Melendez","year":"2012","journal-title":"Addict Biol"},{"issue":"2","key":"ioi200010r66","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.amjmed.2016.10.004","article-title":"Treatment of alcohol use disorder in patients with alcoholic liver disease.","volume":"130","author":"Leggio","year":"2017","journal-title":"Am J Med"},{"key":"ioi200010r43","volume-title":"Structured Clinical Interview for DSM-IV Axis I Disorders\u2014Patient Edition.","author":"First","year":"1997","edition":"Version. 2.0"},{"key":"ioi200010r46","volume-title":"Medical Management Treatment Manual: A Clinical Research Guide for Medically Trained Clinicians Providing Pharmacotherapy as Part of the Treatment for Alcohol Dependence","author":"Pettinati","year":"2004"},{"key":"ioi200010r55","volume-title":"Handbook of Psychiatric Measures","author":"American Psychiatric Association","year":"2000"},{"key":"ioi200010r57","volume-title":"Alcoholism: Developing Drugs for Treatment. Guidance for Industry","author":"Center for Drug Evaluation and Research","year":"2015"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2762700\/jamainternal_anton_2020_oi_200010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T06:33:39Z","timestamp":1695882819000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2762700"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2020.0249","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,1]]}}}